Market Overview:
The global renal diseases drug market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of chronic kidney disease (CKD) and end-stage kidney disease (ESRD) across the globe. In addition, rising awareness about available treatment options for renal diseases is also contributing to the growth of this market. The global renal diseases drug market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into chronic kidney disease drugs, end-stage kidney disease drugs, and others. The chronic kidney disease drugs segment is expected to account for a major share in this market owing to its high prevalence across the globe. On the basis of application, it can be classified into hospitals, specialty clinics, and others segments.
Product Definition:
Renal diseases drug is a type of medication that is prescribed to patients who are suffering from renal diseases. This type of medication helps to improve the function of the kidneys and can help to prevent further damage.
Chronic Kidney Disease (CKD) Drugs:
Chronic kidney disease is a progressive disorder of the kidney which occurs when there is a significant reduction in the function of kidneys. The major symptoms associated with it are chronic fatigue, blood pressure fluctuations, and swelling in legs or feet. According to statistics published by National Kidney Foundation (NKD), approximately 10% of global population suffers from CKD and millions die each year due to lack of treatment or early diagnosis.
End-Stage Kidney Disease (ESRD) Drugs:
The global ERD drugs and it's usage in renal diseases drug market size was valued at USD 4.8 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of chronic kidney disease (CKD) coupled with the growing geriatric population base is primarily driving growth for this sector globally. According to statistics published by National Kidney Foundation, Inc.
Application Insights:
Based on application, the global market is segmented into hospitals, specialty clinics and other. Hospitals held the largest share in 2017 owing to factors such as a large patient base and increasing prevalence of chronic diseases. In addition, hospitals are considered centers of excellence due to advanced healthcare facilities with experienced medical professionals that provide care for patients suffering from renal disorders.
The specialty clinics segment is expected to witness lucrative growth over the forecast period due to an increase in demand for effective treatment options along with rising awareness about available treatments options among patients affected by ESRD or CKD. Furthermore, an increase in incidence rates of ESRD and CKD has led specialty clinics across the globe adopt a proactive approach towards treating these conditions by scheduling follow-up appointments at shorter intervals thus driving demand over the forecast period.
Regional Analysis:
North America dominated the global renal diseases drug market in 2017. The presence of well-established healthcare facilities, favorable government initiatives, and increasing R&D activities for the development of novel therapies are some factors responsible for its large share. Moreover, rising incidence of CKD due to high consumption of alcohol and tobacco is expected to drive growth during the forecast period. According to data published by National Institute on Alcohol Abuse and Alcoholism (NIAAA), in 2015 around 29 million people in U.
Growth Factors:
- Increasing incidence of renal diseases due to changing lifestyles and environmental factors.
- Growing awareness about the early diagnosis and treatment of renal diseases.
- Rising demand for better and innovative therapies for the treatment of renal diseases.
- increasing number of clinical trials for new drugs and therapies for renal diseases 5) technological advancements in the field of diagnostics and therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Renal Diseases Drug Market Research Report
By Type
Chronic Kidney Disease (CKD) Drugs, End-Stage Kidney Disease (ESRD) Drugs,
By Application
Hospitals, Specialty Clinics, Other,
By Companies
Pfizer, Amgen, Roche, GlaxoSmithKline (GSK), Allergan, AbbVie, Kissei Pharmaceutical, AstraZeneca, FibroGen, Sanofi, Teva Pharmaceutical Industries, Johnson & Johnson, Keryx Biopharmaceuticals,
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Renal Diseases Drug Market Report Segments:
The global Renal Diseases Drug market is segmented on the basis of:
Types
Chronic Kidney Disease (CKD) Drugs, End-Stage Kidney Disease (ESRD) Drugs,
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Other,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Amgen
- Roche
- GlaxoSmithKline (GSK)
- Allergan
- AbbVie
- Kissei Pharmaceutical
- AstraZeneca
- FibroGen
- Sanofi
- Teva Pharmaceutical Industries
- Johnson & Johnson
- Keryx Biopharmaceuticals
Highlights of The Renal Diseases Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chronic Kidney Disease (CKD) Drugs
- End-Stage Kidney Disease (ESRD) Drugs
- By Application:
- Hospitals
- Specialty Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Renal Diseases Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Renal diseases drug is a medication used to treat kidney problems.
Some of the major companies in the renal diseases drug market are Pfizer, Amgen, Roche, GlaxoSmithKline (GSK), Allergan, AbbVie, Kissei Pharmaceutical, AstraZeneca, FibroGen, Sanofi, Teva Pharmaceutical Industries, Johnson & Johnson, Keryx Biopharmaceuticals.
The renal diseases drug market is expected to grow at a compound annual growth rate of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Renal Diseases Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Renal Diseases Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Renal Diseases Drug Market - Supply Chain
4.5. Global Renal Diseases Drug Market Forecast
4.5.1. Renal Diseases Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Renal Diseases Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Renal Diseases Drug Market Absolute $ Opportunity
5. Global Renal Diseases Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Renal Diseases Drug Market Size and Volume Forecast by Type
5.3.1. Chronic Kidney Disease (CKD) Drugs
5.3.2. End-Stage Kidney Disease (ESRD) Drugs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Renal Diseases Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Renal Diseases Drug Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Renal Diseases Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Renal Diseases Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Renal Diseases Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Renal Diseases Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Renal Diseases Drug Demand Share Forecast, 2019-2026
9. North America Renal Diseases Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Renal Diseases Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Renal Diseases Drug Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Renal Diseases Drug Market Size and Volume Forecast by Type
9.7.1. Chronic Kidney Disease (CKD) Drugs
9.7.2. End-Stage Kidney Disease (ESRD) Drugs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Renal Diseases Drug Demand Share Forecast, 2019-2026
10. Latin America Renal Diseases Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Renal Diseases Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Renal Diseases Drug Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Renal Diseases Drug Market Size and Volume Forecast by Type
10.7.1. Chronic Kidney Disease (CKD) Drugs
10.7.2. End-Stage Kidney Disease (ESRD) Drugs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Renal Diseases Drug Demand Share Forecast, 2019-2026
11. Europe Renal Diseases Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Renal Diseases Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Renal Diseases Drug Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Renal Diseases Drug Market Size and Volume Forecast by Type
11.7.1. Chronic Kidney Disease (CKD) Drugs
11.7.2. End-Stage Kidney Disease (ESRD) Drugs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Renal Diseases Drug Demand Share, 2019-2026
12. Asia Pacific Renal Diseases Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Renal Diseases Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Renal Diseases Drug Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Renal Diseases Drug Market Size and Volume Forecast by Type
12.7.1. Chronic Kidney Disease (CKD) Drugs
12.7.2. End-Stage Kidney Disease (ESRD) Drugs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Renal Diseases Drug Demand Share, 2019-2026
13. Middle East & Africa Renal Diseases Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Renal Diseases Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Renal Diseases Drug Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Renal Diseases Drug Market Size and Volume Forecast by Type
13.7.1. Chronic Kidney Disease (CKD) Drugs
13.7.2. End-Stage Kidney Disease (ESRD) Drugs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Renal Diseases Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Renal Diseases Drug Market: Market Share Analysis
14.2. Renal Diseases Drug Distributors and Customers
14.3. Renal Diseases Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline (GSK)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Allergan
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. AbbVie
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kissei Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AstraZeneca
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. FibroGen
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sanofi
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Teva Pharmaceutical Industries
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Johnson & Johnson
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Keryx Biopharmaceuticals
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
